FX.co ★ Cocrystal Pharma Gets Positive Result From Phase 1 Study With CDI-988; Stock Up

Cocrystal Pharma, Inc. (COCP) announced on Thursday positive safety and tolerability outcomes from the phase 1 trial's single-ascending dose cohorts for CDI-988, its oral pan-viral norovirus/coronavirus protease inhibitor.

In a study involving healthy adult participants, CDI-988 administered orally in doses ranging from 100 mg to 600 mg was compared with a placebo.

The company reported no serious adverse events or severe treatment-emergent adverse events. Additionally, laboratory assessments, physical exams, and electrocardiograms revealed no clinically significant abnormalities.

As of now, Cocrystal's stock is trading at $2.35, reflecting a 3.97 percent increase on the Nasdaq.